Lung cancer is the leading cause of cancer deaths in the United States. It claims more lives each year than colon, prostate, ovarian and breast cancers combined.
Non-small cell lung cancer (NSCLC), accounts for approximately 85% of new lung cancer diagnoses each year worldwide, including 228,000 in the United States.
NSCLC could have many different types of mutations that may promote the cancer’s growth. It is important for patients to speak with their doctor at the time of diagnosis and when their disease progresses to determine their mutational status.
Until recently, patients have not had a treatment option approved to specifically target the driver of their NSCLC. The U.S. Food and Drug Administration has now approved Tabrecta™ (capmatinib) tablets, for adult patients with metastatic NSCLC whose tumors have a mutation that leads to METex14, as detected by an FDA-approved test.
Learn more here.
